Tag Archives: PEP

Money Pours Into PepsiCo Calls, Illumina Options Light Up Before Earnings

By Caitlin Duffy, Contributor

PEP – , Inc. – Options on global beverage and snack food giant, PepsiCo, were humming with activity this morning after the company posted first-quarter earnings that handily beat analysts’ expectations. Overall volume in PEP options was roughly three times the average daily level for the stock as of 11:00 a.m. ET. Shares in the world’s largest snack maker jumped 5.8% in the early going to a record high of $83.45.

From: http://www.forbes.com/sites/greatspeculations/2013/04/18/money-pours-into-pepsico-calls-illumina-options-light-up-before-earnings/

PepsiCo Quarterly Earnings Fall Even as Revenue Rises

By The Associated Press

Filed under: , , , ,

Chris Rank/Bloomberg via Getty Images

PURCHASE, N.Y. — PepsiCo’s first-quarter profit fell 5 percent, but higher prices lifted the soda and snack maker’s sales.

Adjusted profit topped Wall Street‘s view and the maker of Frito-Lay, Gatorade and other products stood by its full-year earnings forecast, following a year in which it cut costs and invested more heavily in marketing for its biggest brands.

For the period ended March 23, PepsiCo Inc. (PEP) earned $1.08 billion, or 69 cents a share. That’s down from $1.13 billion, or 71 cents a share, a year earlier.

Excluding the impact of Venezuela‘s currency devaluation and other items, per-share earnings rose 12 percent to 77 cents. Analysts expected 70 cents, according to FactSet.

Revenue for the Purchase, N.Y., company rose 1 percent to $12.58 billion, beating analyst expectations of $12.54 billion.

%Gallery-183480%

Permalink | Email this | Linking Blogs | Comments

From: http://www.dailyfinance.com/2013/04/18/pepsico-earnings-fall/

Vaccinate Your Portfolio with These 3 Drugmakers

By Keith Speights, The Motley Fool

Filed under:

Which drug would you rather take: (a) one that treats a disease after you get it, or (b) one that prevents you from getting the disease in the first place? That’s an easy question. Most, if not all of us, would go with answer “b.”We would rather not get the disease at all.

Should this logic apply to investing also? Maybe some of the companies that make those drugs that most of us prefer can help vaccinate our portfolios against the dreaded disease of “hugelossitis.” Here are three vaccine makers that should be attractive to different types of investors.

For the dividend hunter
If you’re hunting for a solid dividend with good growth potential, check out Sanofi . The French drugmaker pays a forward dividend yield of 3.4% and has a five-year average yield of 3.9%. Sure, you can find pharmaceutical firms with higher yields. However, I suspect that when you peek under the covers of most of those companies you’ll find more risk than you’d like.

More than 11% of Sanofi’s revenue stems from sales of human vaccines. The company’s pediatric vaccines that provide protection for multiple diseases — including polio, pertussis, and Hib infections — account for nearly one-third of all vaccine sales. Sanofi’s influenza vaccines such as Fluzone also contribute significantly to the top line, with sales continuing to grow throughout the world.

Sanofi is also a leader in the animal vaccine market through its Merial animal health division. According to global animal health research firm Vetnosis, Merial stands as the top provider in the world for animal vaccines for foot-and-mouth disease, rabies, and bluetongue. 

Shares of Sanofi are up 27% over the last year. The company has several solid pipeline prospects that could boost earnings, including a new vaccine for dengue in a late-stage trial. With good growth prospects and a low price-to-earnings multiple, this established vaccine maker with a nice dividend is one to consider.

For the catastrophe-expecter
Are you the type of investor who is expecting the worst at every corner? Emergent BioSolutions might be just the stock for you. The company makes BioThrax, the only anthrax vaccine approved by the U.S. Food and Drug Administration. If a biological attack using anthrax occurs, this stock will probably be a better investment than gold.

As you might expect, the biggest buyer for BioThrax is the U.S. government. Sales to the Centers for Disease Control and Prevention accounted for $215.3 million of the total $215.9 million in product sales for 2012. However, Emergent is hoping to increase its international sales. The company is also pursuing expansion of BioThrax to a second indication, post-exposure prophylaxis, or PEP

The main concern for investors looking at Emergent is that revenue and earnings have been essentially flat for the past couple of years. The stock hasn’t done all that great lately, either, dropping 15% year-to-date. However, if the company succeeds in its efforts to sell more internationally, the added revenue could provide a boost to the stock. Let’s hope that’s the path to …read more
Source: FULL ARTICLE at DailyFinance

IWF, ORCL, VZ, PEP: ETF Outflow Alert

By ETFChannel.com Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth Index Fund (AMEX: IWF) where we have detected an approximate $68.2 million dollar outflow — that’s a 0.4% decrease week over week (from 255,550,000 to 254,550,000). Among the largest underlying components of IWF, in trading today Oracle Corp. (NASD: ORCL) is up about 0.7%, Verizon Communications Inc (NYSE: VZ) is down about 0.4%, and PepsiCo Inc. (NYSE: PEP) is lower by about 0.1%. For a complete list of holdings, visit the IWF Holdings page »
Source: FULL ARTICLE at Forbes Markets

Julian Andres Klode: Recursive-descent in Python, using generators

Writing recursive descent parsers is easy, especially in Python (just like everything is easy in Python). But Python defines a low limit on the number of recursive calls that can be made, and recursive descent parsers are prone to exceed this limit.

We should thus write our parser without real recursion. Fortunately, Python offers us a way out: Coroutines, introduced in Python 2.5 as per PEP 342. Using coroutines and a simple trampoline function, we can convert every mutually recursive set of functions into a set of coroutines that require constant stack space.

Let’s say our parser looks like this (tokens being an iterator over characters):

def parse(tokens):
    token = next(tokens)
    if token.isalnum():
        return token
    elif token == '(':
         result = parse(tokens)
         if next(tokens) != ')': raise ...
         return result
    else:
         raise ...

We now apply the following transformations:
return X => yield (X)
parse() => (yield parse())

That is, we yield the value we want to return, and we yield a generator whenever we want to call (using a yield expression). Our rewritten parser reads:

def parse(tokens):
    token = next(tokens)
    if token.isalnum():
        yield token
    elif token == '(':
         result = yield parse(tokens)
         if next(tokens) != ')': raise ...
         return result
    else:
         raise ...

We obviously cannot call that generator like the previous function. What we need to introduce is a trampoline. A trampoline is a function that manages that yielded generators, calls them, and passes their result upwards. It looks like this:

def trampoline(generator):
    """Execute the generator using trampolining. """
    queue = collections.deque()

    def schedule(coroutine, stack=(), value=None):
        def resume():
            if 0:
                global prev
                now = stack_len(stack)
                if now < prev:
                    print("Length", now)
                    prev = -1
                elif prev != -1:
                    prev = now
            result = coroutine.send(value)
            if isinstance(result, types.GeneratorType):     # Normal call
                schedule(result, (coroutine, stack))
            elif isinstance(result, Tail):                  # Tail call (if you want to)
                schedule(result.value, stack)
            elif stack:                                     # Return to parent
                schedule(stack[0], stack[1], result)
            else:                                           # Final Return
                return result

        queue.append(resume)

    schedule(generator)

    result = None
    while queue:
        func = queue.popleft()
        result = func()

    return result

This function is based on the code in PEP 342, the difference being that

  • we do not correctly propagate exceptions through the stack, but directly unwind to the caller of the parser (we don’t handle exceptions inside our parser generators anyway)
  • the code actually compiles (code in PEP used ‘value = coroutine.send(value)’ which does not work)
  • the code returns a value (code in PEP was missing a return in schedule)
  • we don’t use a class, and allow only one function to be scheduled at once (yes, we could get rid of the queue)
  • we allow tail calls [where Tail = namedtuple(“Tail”, [“result”])] to save some more memory.

For a more generic version of that, you might want to re-add exception passing, but the exceptions will then have long tracebacks, so I’m not sure how well they will work if you have deep recursion.

Now, the advantage of that is that our parser now requires constant stack space, because the actual real stack is stored in the heap using tuples which are used like singly-linked lists in scheme here. So, the only recursion limit is available memory.

A disadvantage of that transformation is that the code will run slightly slower for small inputs that could be handled using a normally recursive parser.

Filed under: Python
Source: FULL ARTICLE at Planet Ubuntu